Shots:
Taltz has been approved in the US in May 2022 to treat adults & children aged ≥6yrs. with PsO, PsA, AS & nr-axSpA with objective signs of inflammation. The therapy is now available as a citrate-free formulation with an effective treatment along with a well-established safety profile in the US
The new formulation showed a reduction in injection site pain and an 86% reduction in a visual analog scale (VAS) of pain over the original formulation. The safety profile was consistent with the original formulation
The new formulation is expected to be available for new and existing Taltz patients at the end of Aug 2022. The new formulation has been approved by the EMA in Dec 2021
Ref: PR Newswire | Image: Lilly
